This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
June 10 sees robust momentum in biotechnology with novel therapeutic developments, advanced clinical trials, key industry events, and …
The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Already a subscriber? Log in